{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:47:40Z","timestamp":1761821260813},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.nbd.2010.04.007","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T08:51:25Z","timestamp":1272271885000},"page":"130-134","source":"Crossref","is-referenced-by-count":22,"title":["Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease"],"prefix":"10.1016","volume":"40","author":[{"given":"S.F.","family":"Bortvedt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"McLear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Ahern-Rindell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.J.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2010.04.007_bib1","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1073\/pnas.0500055102","article-title":"Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila","volume":"102","author":"Agrawal","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib2","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1073\/pnas.2628045100","article-title":"A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila","volume":"100","author":"Apostol","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2010.04.007_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1471-4159.2004.02839.x","article-title":"Tissue transglutaminase contributes to disease progression in the R6\/2 Huntington's disease mouse model via aggregate-independent mechanisms","volume":"92","author":"Bailey","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.04.007_bib5","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1073\/pnas.0511256103","article-title":"Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases","volume":"103","author":"Bodner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2010.04.007_bib7","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.04.007_bib8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2010.04.007_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1471-4159.2004.02726.x","article-title":"Cystamine increases l-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation","volume":"91","author":"Fox","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.04.007_bib10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2010.04.007_bib11","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib12","first-page":"971","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"Huntington's Disease Collaborative Research Group","year":"1993"},{"key":"10.1016\/j.nbd.2010.04.007_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2010.04.007_bib14","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.96.13.7388","article-title":"Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei","volume":"96","author":"Karpuj","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.287.5459.1837","article-title":"Genetic suppression of polyglutamine toxicity in Drosophila","volume":"287","author":"Kazemi-Esfarjani","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.nbd.2010.04.007_bib16","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","article-title":"Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease","volume":"98","author":"Lecerf","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib17","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1074\/jbc.M205812200","article-title":"Cystamine inhibits caspase activity Implications for the treatment of polyglutamine disorders","volume":"278","author":"Lesort","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2010.04.007_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00240602","article-title":"Transglutaminases","volume":"58","author":"Lorand","year":"1984","journal-title":"Mol. Cell. Biochem."},{"issue":"Spec No 2","key":"10.1016\/j.nbd.2010.04.007_bib19","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1093\/hmg\/ddg271","article-title":"Fly models of Huntington's disease","volume":"12","author":"Marsh","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2010.04.007_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuron.2006.09.025","article-title":"Drosophila in the study of neurodegenerative disease","volume":"52","author":"Marsh","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2010.04.007_bib21","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1096\/fj.07-099689","article-title":"Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease","volume":"22","author":"McLear","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2010.04.007_bib22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/14712590903176387","article-title":"Developing intrabodies for the therapeutic suppression of neurodegenerative pathology","volume":"9","author":"Messer","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2010.04.007_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ymthe.2005.04.003","article-title":"Intrabody applications in neurological disorders: progress and future prospects","volume":"12","author":"Miller","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2010.04.007_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2004.11.003","article-title":"A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease","volume":"19","author":"Miller","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2010.04.007_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1460-9568.2005.03895.x","article-title":"A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease","volume":"21","author":"Morton","year":"2005","journal-title":"Eur. J. NeuroSci."},{"issue":"10 Suppl","key":"10.1016\/j.nbd.2010.04.007_bib26","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/nm1066","article-title":"Protein aggregation and neurodegenerative disease","author":"Ross","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2010.04.007_bib27","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.neuroscience.2006.05.043","article-title":"Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease","volume":"141","author":"Ryu","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2010.04.007_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/hmg\/ddm294","article-title":"A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin","volume":"17","author":"Sarkar","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2010.04.007_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2010.04.007_bib30","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.04.007_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2010.04.007_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2010.04.007_bib33","first-page":"17","article-title":"Intracellular antibodies: a revolution waiting to happen?","volume":"8","author":"Stocks","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.nbd.2010.04.007_bib34","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nsmb.1700","article-title":"The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation","volume":"16","author":"Tam","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.nbd.2010.04.007_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.nbd.2010.04.007_bib36","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1111\/j.1742-4658.2008.06561.x","article-title":"Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases","volume":"275","author":"Truant","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.nbd.2010.04.007_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.04.007_bib38","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.nbd.2010.04.007_bib39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jmb.2009.12.017","article-title":"Modulation of polyglutamine conformations and dimer formation by the N-terminus of huntingtin","volume":"396","author":"Williamson","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2010.04.007_bib40","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","article-title":"Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies","volume":"102","author":"Wolfgang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2010.04.007_bib41","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611000104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611000104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:45:28Z","timestamp":1559069128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999611000104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S096999611000104X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2010.04.007","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}